N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 577-581

  Oyama, Tsunehiro ^a,c   Kawamoto, Toshihiro ^a   Mizoue, Tetsuya ^a   Yasumoto, Kosei ^a   Kodama, Yasushi ^a   Mitsudomi, Tetsuya ^a,b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Carbone LAB ^*  (United States)

Author keywords

Genetic susceptibility; Lung cancer; N acetylation polymorphism; p53 gene mutation; Prevention

Indexed keywords

ACYLTRANSFERASE; CARCINOGEN; PROTEIN P53;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; INCIDENCE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLISM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; SQUAMOUS CELL CARCINOMA;

ACETYLATION; ACETYLTRANSFERASES; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0031044557     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Minna JD, Pass H, Glatstein E and Ihde, DC: Cancer of the lung. In: VT De Vita, S Hellman, and SA. Rosenberg (eds). Cancer: Principles and Practice of Oncology, pp. 591-705, Philadelphia: JB Lippincott, 1989.
2. Doll R and Peto R: The Causes of Cancer. New York: Oxford university Press, 1981.
3. Smith CAD, Smith G and Wolf CR: Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A: 1921-1935, 1994.
4. Weber, WW and Hein, DW: N-acetylation pharmacogenetics. Pharmacol Rev. 37: 25-29, 1985.
5. Evans, DAP: N-acetyltransferase. Pharmacol Ther 42: 157-234, 1989.
6. Hein DW: Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta 948: 37-66, 1988.
7. Lang NP, Chu DZJ, Hunter CF, Kendall DC, Flammang TS, and Kadlubar FF: Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 121: 1259-1261, 1986.
8. Ilett KF, David BM, Detchon P, Castleden WM and Kwa, R-Acetylation phenotype in colorectal carcinoma. Cancer Res 7: 1466-1469, 1987.
9. Deguchi T, Mashimo M and Suzuki T: Correlation between acetylator phenotypes and genotypes of polymorphic arylamine Nacetyltransferase in human liver. J Biol Chem 265: 12757-12760, 1990.
10. Mashimo M, Suzuki T, Abe M and Deguchi T: Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 90: 139-143, 1992.
11. Abe M, Suzuki T and Deguchi T: An improved method for genotyping of N-acetyltransferase polymorphism by polymerase chain reaction Jpn J Human Genet 38: 163-168, 1993.
12. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DJ, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y: Nomenclature for N-acetyl transterases. Pharmacogenetics 5: 1-17, 1995
13. Minna JD: The molecular biology of lung cancer pathogenesis Chest, 103: 445S-456S, 1993.
14. Davis LG, Dibner MD and Battey JF: Basic methods in molecular biology. New York: Elsevier. 1986.
15. Ohsako S and Deguchi T: Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 265: 4630-4634, 1990.
16. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85: 2018-2023, 1993.
17. SAS #Institute. The GLM procedure. In: SAS/STAT™ User's Guide Release 6.03, pp. 519-548 Cary NC: SAS Institute, 1988.
18. Shibuta K, Nakashima T, Abe M, Mashimo M, Mori M, Ueo H, Akiyoshi T, Sugimachi K, and Suzuki T: Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 74: 3108-3112, 1994.
19. Philip PA. Fitzgerald DL, Cartwright RA: Peake MD and Rogers HJ: Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis 9: 491-493, 1988.
20. Tokuhata, GK and Lilienfield AM: Familial aggregation of lung cancer in humans. J Natl Cancer Inst 30: 289-312, 1963.
21. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE and Rothschild H: Increased familial risk for lung cancer. J Natl Cancer Inst 76: 217-222, 1986.
22. Caporaso NG, Tucker MA, Hoover RN, Haves RB, Pickle LW, Issaq HJ, Muschik GM, Green-Gallo L, Buivys D, Aisner S, Resau JH, Trump BF, Tollerud D, Weston A and Harris CC: Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 82: 1268-1272, 1990.
23. Hayashi S, Watanabe J, and Kawajiri K: High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Muclass glutathione S-transferase gene. Jpn J Cancer Res 83: 866-870, 1992.
24. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, and Takahashi T: p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res 52: 734-736, 1992.
25. Greenblatt MS, Benett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
26. Oda Y, Tanuka M and Nakanishi I: Relation between the occurrence of K-ras gene point mutation and genotypes of polymorphic N-acetyltransferase in human colorectal carcinoma. Carcinogenesis 15: 1365-1369 1994.